Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022 Post published:June 9, 2022 Post category:Press Release
Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies Post published:June 8, 2022 Post category:Press Release
Enveric Biosciences to Participate in Upcoming Conferences in June 2022 Post published:June 8, 2022 Post category:Press Release
PharmaTher Announces Positive Results from Study of KETABETâ„¢ for Depression Post published:June 7, 2022 Post category:Press Release
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Post published:June 6, 2022 Post category:Press Release
Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato; Another KAP Provider Launches; Canadian Province Decriminalises Possession of MDMA and Other Drugs Post published:June 3, 2022 Post category:Psychedelic Bulletin
Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea Post published:June 3, 2022 Post category:Press Release
Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022 Post published:June 3, 2022 Post category:Press Release
Psychedelic Research Bulletin: May 2022 Post published:June 2, 2022 Post category:Psychedelics Research Review